Plasma proteome-wide Mendelian randomization reveals multi-ancestry drug targets for gastric cancer

Background Gastric cancer (GC) exhibits marked epidemiological differences between European (EUR) and East Asian (EAS) populations, with significantly higher incidence rates in EAS. Circulating proteins represent promising drug targets; however, most proteomic studies have focused primarily on EUR ancestry, leaving EAS-specific targets largely underexplored. This study aims to identify ancestry-specific plasma protein targets for GC using Mendelian randomization (MR). Methods We employed Mendelian randomization (MR) and colocalization approaches to assess the putative causal effects of plasma proteins on GC risk across diverse populations. Specifically, we examined proteins in EUR and EAS populations. Subsequent single-cell RNA sequencing and molecular docking were conducted to identify cellular expression patterns and potential therapeutic compounds. Finally, experiments were conducted to verify the newly discovered drug target. Results Our analyses revealed four significant protein targets in the EUR population (SLURP1, ANGPTL3, NME4, ANXA10) and nine in the EAS population (ICAM5, SMOC1, PSCA, SATB1, SCRG1, PTPRB, ISLR2, NCR3LG1, SELE) associated with GC susceptibility. These drug targets are mainly expressed in epithelial cells, and Pit mucous cells in gastric tumor tissue. Experimental validation indicated significant downregulation of NME4 and upregulation of ICAM5 in GC cell lines and tissue samples, suggesting potential tumor-suppressive and oncogenic functions, respectively. Moreover, molecular docking identified seven repurposable drugs, with digoxin demonstrating cross-ancestry therapeutic potential. Conclusion Our findings delineate 13 ancestry-specific protein targets, including five novel candidates, thereby enhancing our understanding of GC pathogenesis. This study underscores the importance of ancestral diversity in informing drug development strategies for GC. Future research should focus on validating these targets and exploring their functional mechanisms further to translate these findings into clinical applications.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-05-01
DOI
https://doi.org/10.3389/fonc.2026.1821512
Primary Topic
Ferroptosis and cancer prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Plasma proteome-wide Mendelian randomization reveals multi-ancestry drug targets for gastric cancer

Chenghui Zhao, Yuxing Wang, Peng Zhi, Zhengyao Chang et al.
Frontiers in Oncology
Ferroptosis and cancer prognosis
article

Plasma proteome-wide Mendelian randomization reveals multi-ancestry drug targets for gastric cancer

Chenghui Zhao, Yuxing Wang, Peng Zhi, Zhengyao Chang, Juanjuan Yan, Jie Geng, Yan Cui, Lingyu Qiao, Guanghui Xue, Yinmei Xu
article en

Abstract

Background Gastric cancer (GC) exhibits marked epidemiological differences between European (EUR) and East Asian (EAS) populations, with significantly higher incidence rates in EAS. Circulating proteins represent promising drug targets; however, most proteomic studies have focused primarily on EUR ancestry, leaving EAS-specific targets largely underexplored. This study aims to identify ancestry-specific plasma protein targets for GC using Mendelian randomization (MR). Methods We employed Mendelian randomization (MR) and colocalization approaches to assess the putative causal effects of plasma proteins on GC risk across diverse populations. Specifically, we examined proteins in EUR and EAS populations. Subsequent single-cell RNA sequencing and molecular docking were conducted to identify cellular expression patterns and potential therapeutic compounds. Finally, experiments were conducted to verify the newly discovered drug target. Results Our analyses revealed four significant protein targets in the EUR population (SLURP1, ANGPTL3, NME4, ANXA10) and nine in the EAS population (ICAM5, SMOC1, PSCA, SATB1, SCRG1, PTPRB, ISLR2, NCR3LG1, SELE) associated with GC susceptibility. These drug targets are mainly expressed in epithelial cells, and Pit mucous cells in gastric tumor tissue. Experimental validation indicated significant downregulation of NME4 and upregulation of ICAM5 in GC cell lines and tissue samples, suggesting potential tumor-suppressive and oncogenic functions, respectively. Moreover, molecular docking identified seven repurposable drugs, with digoxin demonstrating cross-ancestry therapeutic potential. Conclusion Our findings delineate 13 ancestry-specific protein targets, including five novel candidates, thereby enhancing our understanding of GC pathogenesis. This study underscores the importance of ancestral diversity in informing drug development strategies for GC. Future research should focus on validating these targets and exploring their functional mechanisms further to translate these findings into clinical applications.

Frontiers in OncologyVol. 16
Shanxi Medical University (CN), Beijing University of Chinese Medicine (CN), Chinese PLA General Hospital (CN), Affiliated Hospital of Shaanxi University of Chinese Medicine (CN), Shanxi University of Traditional Chinese Medicine (CN)
Good health and well-being
Openalex Percentile: Top 8%
Ferroptosis and cancer prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.